US Dollar Index at 104.88 US. 10-year bond yield at 4.
42% Brent crude down 0.82% at $81.23 per barrel Nymex crude down 0.
94% at $76.84 per barrel Bitcoin was up 0.15% at $69,516.
69 GIFT Nifty was 1.5 points or 0.01% lower at 22,648.
50 as of 7:37 a.m. Revenue up 13% at Rs 1,215 crore vs Rs 1,075 crore Ebitda up 18.
5% at Rs 139 crore vs Rs 117 crore Margin at 11.4% vs 10.9% Net profit down 41% at Rs 71 crore vs Rs 122 crore Citi Research maintains 'buy' On Cipla with a target price of Rs 1,650 apiece, implying a potential upside of 11% Lanreotide acetate: ANDA approval could accelerate Cipla's market share Current market share is hovering around 20% Lanreotide (brand and generic) market is approximately $900m in the US.
US sales could rise by $100m next year if market share rises to 35–40% The brokerage maintains 'buy' on Sun Pharma with a target price of Rs 1,640 per share, an upside of 4.8% from the previous close. Guidance indicates margin pressure in FY25.
Top line expected to grow in high single digits. FY25 to be year of investments due to higher research and development spends related to new launches. Possibility for subdued margins in FY25 and stock may be under pressure in near term.
Underlying business trends and medium/long-term margin-expansion story remains intact. Revenue up 24.6% to Rs 3,052 crore from Rs 2,448 crore Ebitda up 14.
3% to Rs 635 crore vs Rs 556 crore Margin at 20.8% vs 22.7% Net profit at Rs 254 crore vs loss of Rs 45 crore Nuvama maintains 'buy' .
